VIDEO: ‘Long way to go’ in HCV treatment, elimination

ByPaul Kwo, MD

ByMarley V. Ghizzone

Fact checked byHeather Biele

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses recent efforts to advance elimination of hepatitis C virus.

At the ACG Annual Scientific Meeting, Kwo delivered a talk about screening recommendations and treatment options for patients with HCV.

“The treatment of hepatitis C ... has been highly successful through direct-acting anti-viral agents, but we still have a long way to go,” he told Healio. “The pandemic certainly halted our ability to pursue our elimination goals for hepatitis C, but we are now moving forward with trying to eliminate and reengage individuals.”

Published by:

Sources/Disclosures

Collapse

Source:

Kwo P. Learning luncheon 01: Hepatitis C: Far from over. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).

Disclosures: Kwo reports serving as an advisor or review panel member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect.

Discoveries in Liver

Read more

VIDEO: ‘Long way to go’ in HCV treatment, elimination

Related Content